Farhad Ravandi-Kashani

Clinical trials

• A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

  Principal investigator · Terminated · Phase 1

  M.D. Anderson Cancer Center

  2023–2026
• ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  Principal investigator · Recruiting · Phase 1, Phase 2

  M.D. Anderson Cancer Center

  2021–2028
• Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

  Principal investigator · Active not recruiting · Phase 2

  M.D. Anderson Cancer Center

  2021–2026
• Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

  Principal investigator · Terminated · Phase 1, Phase 2

  M.D. Anderson Cancer Center

  2018–2024